For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Neuracle Science Co., Ltd.

Calculating rank

USPTO Granted Patents = 21

EPO Patents = 3

Forward Citations = 68

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Bongcheol Kim (14 out of 14 patents)

Dong Sik Kim (12 out of 22 patents)

Jae Young Seong (9 out of 10 patents)

4. Jae-Keun Lee (7 out of 16 patents)

5. Junho Chung (6 out of 22 patents)

6. Eun Bee Cho (6 out of 7 patents)

7. Junyeong Jin (6 out of 8 patents)

8. Soon-gu Kwon (6 out of 6 patents)

9. Jong Ik Hwang (5 out of 8 patents)

10. Woong Sun (3 out of 5 patents)

11. Won-Ki Kim (3 out of 4 patents)

12. Juwon Shim (3 out of 3 patents)

13. Tae Young Yune (2 out of 4 patents)

14. Jong-Ik Hwang (2 out of 3 patents)

15. Dong-Hoon Kim (2 out of 44 patents)

21 patents: Sort by Forward Citations

1. 12492246 - ANTI-FAM19A5 ANTIBODIES AND USES THEREOF (2025-12-09),

2. 12492244 - ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF (2025-12-09),

3. 12466880 - USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF GLAUCOMA (2025-11-11),

4. 12459995 - Use of anti-FAM19A5 antibodies (2025-11-04),

5. 12435130 - Pharmaceutical use of FAM19A5 involved in regulating gliogenesis (2025-10-07),

6. 12247070 - Use of anti-FAM19A5 antibodies for treating atherosclerosis (2025-03-11),

7. 12215338 - Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies (2025-02-04),

8. 12202889 - Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof (2025-01-21),

9. 12077579 - Use of anti-FAM19A5 antibodies for treating fibrosis (2024-09-03),

10. 12072339 - Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders (2024-08-27),

11. 11970532 - Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof (2024-04-30),

12. 11746149 - Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma (2023-09-05),

13. 11739141 - Pharmaceutical use of FAM19A5 involved in regulating gliogenesis (2023-08-29),

14. 11634484 - Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain (2023-04-25),

15. 11618783 - Anti-FAM19A5 antibodies and uses thereof (2023-04-04),

Company Overview

Neuracle Science Co., Ltd. is a pioneering company based in Seoul, South Korea, specializing in advanced neurotechnology solutions. The organization focuses on developing innovative medical devices and software aimed at enhancing brain health and cognitive function. With a commitment to research and development, Neuracle integrates cutting-edge neuroscience with engineering to create products that address various neurological conditions. Their work contributes to the growing field of brain-computer interfaces and neurorehabilitation, positioning them as a key player in the healthcare technology landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

21 Patents

#222 in Seoul

#613 in South Korea

#30,018 in the World

Seoul, South Korea

Neuracle Science Co., Ltd.

Forward Citations = 68

29 inventors:

Bongcheol Kim (14 out of 14 patents)

Dong Sik Kim (12 out of 22 patents)

Jae Young Seong (9 out of 10 patents)

4. Jae-Keun Lee (7 out of 16 patents)

5. Junho Chung (6 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neuracle Science Co., Ltd.. Retrieved from https://idiyas.com/company/neuracle-science-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…